Across the recent three months, 16 analysts have shared their insights on Taysha Gene Therapies TSHA, expressing a variety of opinions spanning from bullish to bearish.
The table below provides a snapshot of their recent ratings, showcasing how sentiments have evolved over the past 30 days and comparing them to the preceding months.
| Bullish | Somewhat Bullish | Indifferent | Somewhat Bearish | Bearish | |
|---|---|---|---|---|---|
| Total Ratings | 8 | 8 | 0 | 0 | 0 |
| Last 30D | 1 | 0 | 0 | 0 | 0 |
| 1M Ago | 0 | 1 | 0 | 0 | 0 |
| 2M Ago | 3 | 4 | 0 | 0 | 0 |
| 3M Ago | 4 | 3 | 0 | 0 | 0 |
Analysts have set 12-month price targets for Taysha Gene Therapies, revealing an average target of $7.06, a high estimate of $9.00, and a low estimate of $5.00. Observing a 20.07% increase, the current average has risen from the previous average price target of $5.88.
Investigating Analyst Ratings: An Elaborate Study
In examining recent analyst actions, we gain insights into how financial experts perceive Taysha Gene Therapies. The following summary outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
| Analyst | Analyst Firm | Action Taken | Rating | Current Price Target | Prior Price Target |
|---|---|---|---|---|---|
| Gil Blum | Needham | Maintains | Buy | $7.00 | $7.00 |
| Kristen Kluska | Cantor Fitzgerald | Maintains | Overweight | $7.00 | $7.00 |
| Kristen Kluska | Cantor Fitzgerald | Maintains | Overweight | $7.00 | $7.00 |
| Gil Blum | Needham | Maintains | Buy | $7.00 | $7.00 |
| Eun Yang | Jefferies | Raises | Buy | $8.00 | $2.00 |
| Gil Blum | Needham | Maintains | Buy | $7.00 | $7.00 |
| Kristen Kluska | Cantor Fitzgerald | Maintains | Overweight | $7.00 | - |
| Kristen Kluska | Cantor Fitzgerald | Maintains | Overweight | $7.00 | - |
| Kristen Kluska | Cantor Fitzgerald | Maintains | Overweight | $7.00 | - |
| Gil Blum | Needham | Maintains | Buy | $7.00 | - |
| Christopher Raymond | Piper Sandler | Announces | Overweight | $9.00 | - |
| Whitney Ijem | Canaccord Genuity | Maintains | Buy | $7.00 | - |
| Geulah Livshits | Chardan Capital | Raises | Buy | $7.00 | $5.00 |
| Silvan Tuerkcan | JMP Securities | Maintains | Market Outperform | $5.00 | - |
| Kristen Kluska | Cantor Fitzgerald | Maintains | Overweight | $7.00 | - |
| Gil Blum | Needham | Raises | Buy | $7.00 | $5.00 |
Key Insights:
- Action Taken: In response to dynamic market conditions and company performance, analysts update their recommendations. Whether they 'Maintain', 'Raise', or 'Lower' their stance, it signifies their reaction to recent developments related to Taysha Gene Therapies. This insight gives a snapshot of analysts' perspectives on the current state of the company.
- Rating: Offering insights into predictions, analysts assign qualitative values, from 'Outperform' to 'Underperform'. These ratings convey expectations for the relative performance of Taysha Gene Therapies compared to the broader market.
- Price Targets: Analysts explore the dynamics of price targets, providing estimates for the future value of Taysha Gene Therapies's stock. This examination reveals shifts in analysts' expectations over time.
Navigating through these analyst evaluations alongside other financial indicators can contribute to a holistic understanding of Taysha Gene Therapies's market standing. Stay informed and make data-driven decisions with our Ratings Table.
Stay up to date on Taysha Gene Therapies analyst ratings.
If you are interested in following small-cap stock news and performance you can start by tracking it here.
About Taysha Gene Therapies
Taysha Gene Therapies Inc is a patient-centric gene therapy company to eradicate monogenic CNS disease. It is focused on developing and commercializing AAV-based gene therapies for the treatment of monogenic diseases of the CNS in both rare and large patient populations. The company develops and commercializes transformative gene therapy treatments. Its product pipeline includes TSHA-102 which is a is a self-complementary intrathecally delivered AAV9 gene transfer therapy in clinical evaluation for Rett syndrome.
Financial Insights: Taysha Gene Therapies
Market Capitalization Analysis: The company's market capitalization is above the industry average, indicating that it is relatively larger in size compared to peers. This may suggest a higher level of investor confidence and market recognition.
Revenue Growth: Taysha Gene Therapies's revenue growth over a period of 3 months has faced challenges. As of 31 March, 2024, the company experienced a revenue decline of approximately -27.52%. This indicates a decrease in the company's top-line earnings. As compared to competitors, the company encountered difficulties, with a growth rate lower than the average among peers in the Health Care sector.
Net Margin: Taysha Gene Therapies's financial strength is reflected in its exceptional net margin, which exceeds industry averages. With a remarkable net margin of -705.39%, the company showcases strong profitability and effective cost management.
Return on Equity (ROE): Taysha Gene Therapies's ROE lags behind industry averages, suggesting challenges in maximizing returns on equity capital. With an ROE of -37.37%, the company may face hurdles in achieving optimal financial performance.
Return on Assets (ROA): The company's ROA is below industry benchmarks, signaling potential difficulties in efficiently utilizing assets. With an ROA of -14.77%, the company may need to address challenges in generating satisfactory returns from its assets.
Debt Management: Taysha Gene Therapies's debt-to-equity ratio stands notably higher than the industry average, reaching 1.13. This indicates a heavier reliance on borrowed funds, raising concerns about financial leverage.
The Basics of Analyst Ratings
Within the domain of banking and financial systems, analysts specialize in reporting for specific stocks or defined sectors. Their work involves attending company conference calls and meetings, researching company financial statements, and communicating with insiders to publish "analyst ratings" for stocks. Analysts typically assess and rate each stock once per quarter.
Some analysts also offer predictions for helpful metrics such as earnings, revenue, and growth estimates to provide further guidance as to what to do with certain tickers. It is important to keep in mind that while stock and sector analysts are specialists, they are also human and can only forecast their beliefs to traders.
This article was generated by Benzinga's automated content engine and reviewed by an editor.
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
date | ticker | name | Price Target | Upside/Downside | Recommendation | Firm |
|---|
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
